By Finance Pulse in Novo Nordisk —

Novo Nordisk Shares Fall on CagriSema Trial Setback

Novo Nordisk's stock experienced a decline following underwhelming results from the CagriSema trial, impacting investor sentiment. Stay updated with the latest insights.

A stylized graph depicting a downward trend, symbolizing stock market fluctuations, with subtle blue
Novo Nordisk Shares Fall on CagriSema Trial Setback

Novo Nordisk's stock slid due to disappointing CagriSema trial results.

Source